Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients - Results of the Austrian cohort of the ECHO study

Wiener Klinische Wochenschrift

Volumn 123, Issue 1-2, 2011, Pages 45-52

  Zitt, Emanuel ^a   Jäger, Christine ^b   Rosenkranz, Alexander R ^c   Eigner, Manfred ^d   Kodras, Katharina ^e   Kovarik, Josef ^f   Graf, Helmut ^g   Pétavy, Frank ^h   Horn, Sabine ⁱ   Watschinger, Bruno ^e  

^a Landeskrankenhaus Feldkirch   (Austria)

^b AMGEN INC   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d SMZ Süd Kaiser Franz Josef Spital Vienna ^*  (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f WILHELMINEN HOSPITAL   (Austria)

^g KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^h AMGEN LTD   (United Kingdom)

ⁱ MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Calcimimetic; Cinacalcet; Dialysis; Hyperphosphataemia; Secondary hyperparathyroidism

Indexed keywords

ALUMINUM DERIVATIVE; CALCIUM; CALCIUM DERIVATIVE; CINACALCET; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; BONE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CHEMICAL PARAMETERS; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MOTIVATION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARATHYROID GLAND; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SERUM; TREATMENT DURATION;

AUSTRIA; COHORT STUDIES; DIALYSIS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79952280308     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-010-1515-x     Document Type: Article

References (38)

1. E Slatopolsky A Brown A Dusso 1999 Pathogenesis of secondary hyperparathyroidism Kidney Int Suppl 73 S14 S19 1:CAS:528:DC%2BD3cXivFKitw%3D%3D 10.1046/j.1523-1755.1999.07304.x 10633458
2. WG Goodman J Goldin BD Kuizon C Yoon B Gales D Sider, et al. 2000 Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis N Engl J Med 342 1478 1483 1:STN:280: DC%2BD3c3ls1OjtA%3D%3D 10.1056/NEJM200005183422003 10816185 (Pubitemid 30318271)
3. P Raggi A Boulay S Chasan-Taber N Amin M Dillon SK Burke, et al. 2002 Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39 695 701 10.1016/S0735-1097(01)01781-8 11849871 (Pubitemid 34158168)
4. S Ribeiro A Ramos A Brandao JR Rebelo A Guerra C Resina, et al. 1998 Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism Nephrol Dial Transplant 13 2037 2040 1:CAS:528:DyaK1cXlslajtbg%3D 10.1093/ndt/13.8.2037 9719161 (Pubitemid 28356772)
5. GA Block PS Klassen JM Lazarus N Ofsthun EG Lowrie GM Chertow 2004 Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 2208 2218 1:CAS:528:DC%2BD2cXlvVKmu7w%3D 10.1097/01.ASN. 0000133041.27682.A2 15284307 (Pubitemid 39031360)
6. ML Melamed JA Eustace LC Plantinga BG Jaar NE Fink RS Parekh, et al. 2008 Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study Nephrol Dial Transplant 23 1650 1658 1:CAS:528:DC%2BD1cXkvF2gtrg%3D 10.1093/ndt/gfm849 18065788 (Pubitemid 351767752)
7. F Tentori MJ Blayney JM Albert BW Gillespie PG Kerr J Bommer, et al. 2008 Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis 52 519 530 1:CAS:528:DC%2BD1cXhtFOrt7zF 10.1053/j.ajkd.2008.03. 020 18514987
8. H Malluche MC Faugere 1990 Renal bone disease 1990: an unmet challenge for the nephrologist Kidney Int 38 193 211 1:STN:280:DyaK3czosVSrtw%3D%3D 10.1038/ki.1990.187 2205749 (Pubitemid 20324978)
9. S Moe T Drueke J Cunningham W Goodman K Martin K Olgaard, et al. 2006 Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 69 1945 1953 1:STN:280:DC%2BD283ptl2nug%3D%3D 10.1038/sj.ki.5000414 16641930 (Pubitemid 43924257)
10. Anonymous 2003 K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 S1 S201
11. Anonymous 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl 113 S1 S130
12. EW Young T Akiba JM Albert JT McCarthy PG Kerr DC Mendelssohn, et al. 2004 Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis 44 34 38 10.1016/S0272-6386(04)01103-5 15486872
13. MD Danese V Belozeroff K Smirnakis KJ Rothman 2008 Consistent control of mineral and bone disorder in incident hemodialysis patients Clin J Am Soc Nephrol 3 1423 1429 10.2215/CJN.01060308 18596117
14. Kramar R,Oberbauer R. Austrian Dialysis and Transplantation Registry (OEDTR), Annual Report 2008. Austrian Society of Nephrology; 2008
15. GA Block TE Hulbert-Shearon NW Levin FK Port 1998 Association of serum phosphorus and calcium×phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 31 607 617 1:STN:280:DyaK1c7ovFKlsw%3D%3D 10.1053/ajkd.1998.v31.pm9531176 9531176
16. GA Block FK Port 2000 Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management Am J Kidney Dis 35 1226 1237 1:STN:280: DC%2BD3czgsFeltg%3D%3D 10.1016/S0272-6386(00)70064-3 10845841 (Pubitemid 30354431)
17. SM Moe TB Drueke 2003 Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product Am J Nephrol 23 369 379 1:CAS:528:DC%2BD3sXptVWktrY%3D 10.1159/000073945 14551461 (Pubitemid 37465098)
18. EF Nemeth ME Steffey LG Hammerland BC Hung BC Van Wagenen EG DelMar, et al. 1998 Calcimimetics with potent and selective activity on the parathyroid calcium receptor Proc Natl Acad Sci USA 95 4040 4045 1:CAS:528: DyaK1cXitlKisrk%3D 10.1073/pnas.95.7.4040 9520489 (Pubitemid 28173250)
19. GA Block KJ Martin AL de Francisco SA Turner MM Avram MG Suranyi, et al. 2004 Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 1516 1525 1:CAS:528:DC%2BD2cXjtVeqtLY%3D 10.1056/NEJMoa031633 15071126 (Pubitemid 38477776)
20. JS Lindberg B Culleton G Wong MF Borah RV Clark WB Shapiro, et al. 2005 Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study J Am Soc Nephrol 16 800 807 1:CAS:528: DC%2BD2MXis12nsr4%3D 10.1681/ASN.2004060512 15689407 (Pubitemid 41725117)
21. P Urena SH Jacobson E Zitt M Vervloet F Malberti N Ashman, et al. 2009 Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice - the ECHO observational study Nephrol Dial Transplant 24 2852 2859 1:CAS:528:DC%2BD1MXhtVGqu7jI 10.1093/ndt/gfp144 19369690
22. J Cunningham M Danese K Olson P Klassen GM Chertow 2005 Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism Kidney Int 68 1793 1800 1:CAS:528:DC%2BD2MXhtFequ7vI 10.1111/j.1523-1755.2005.00596.x 16164656 (Pubitemid 43169924)
23. GM Chertow LB Pupim GA Block R Correa-Rotter TB Drueke J Floege, et al. 2007 Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview Clin J Am Soc Nephrol 2 898 905 1:CAS:528:DC%2BD2sXhsVGqt7zE 10.2215/CJN.04381206 17702710
24. A Arnold MF Brown P Urena RD Gaz E Sarfati TB Drueke 1995 Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia J Clin Invest 95 2047 2053 1:CAS:528:DyaK2MXltlWrtrk%3D 10.1172/JCI117890 7738171
25. TB Drueke 2000 Cell biology of parathyroid gland hyperplasia in chronic renal failure J Am Soc Nephrol 11 1141 1152 1:CAS:528:DC%2BD3cXktF2hu7Y%3D 10820180 (Pubitemid 30367946)
26. IZ Ben-Dov H Galitzer V Lavi-Moshayoff R Goetz M Kuro-o M Mohammadi, et al. 2007 The parathyroid is a target organ for FGF23 in rats J Clin Invest 117 4003 4008 1:CAS:528:DC%2BD2sXhsValsLzL 17992255 (Pubitemid 350224109)
27. H Komaba S Goto H Fujii Y Hamada A Kobayashi K Shibuya, et al. 2010 Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients Kidney Int 77 232 238 1:CAS:528: DC%2BC3cXntVemtQ%3D%3D 10.1038/ki.2009.414 19890272
28. I Ohkido K Yokoyama A Imura Y Utsunomiya T Hosoya Y Nabeshima 2010 Persistent alpha-Klotho (a-Kl) expression in theparathyroid glands of patients with secondary hyperparathyroidism Nephrol Dial Transplant 25 1007 1008 1:CAS:528:DC%2BC3cXislajtr4%3D 10.1093/ndt/gfp743 20075437
29. Y Tominaga Y Tanaka K Sato T Nagasaka H Takagi 1997 Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism Semin Surg Oncol 13 78 86 1:STN:280:DyaK2s3ktlSrsQ%3D%3D 10.1002/(SICI)1098-2388(199703/04)13:2<78::AID-SSU3>3.0.CO;2-Z 9088063 (Pubitemid 27146980)
30. H Komaba M Fukagawa 2009 Regression of parathyroid hyperplasia by calcimimetics - fact or illusion? Nephrol Dial Transplant 24 707 709 10.1093/ndt/gfn717 19103739
31. M Mizobuchi I Hatamura H Ogata F Saji S Uda K Shiizaki, et al. 2004 Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency J Am Soc Nephrol 15 2579 2587 1:CAS:528:DC%2BD2cXnslOnu7k%3D 10.1097/01.ASN.0000141016. 20133.33 15466262 (Pubitemid 41103364)
32. ME Rodriguez Y Almaden S Canadillas A Canalejo E Siendones I Lopez, et al. 2007 The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands Am J Physiol Renal Physiol 292 F1390 F1395 1:CAS:528:DC%2BD2sXlslShtbc%3D 10.1152/ajprenal.00262.2006 17200160 (Pubitemid 46701865)
33. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2010;Dec 10 (Epub ahead of print)
34. EH Jeffery K Abreo E Burgess J Cannata JL Greger 1996 Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney J Toxicol Environ Health 48 649 665 1:CAS:528:DyaK28XltlKitrg%3D 10.1080/009841096161122 8772804 (Pubitemid 26285837)
35. SW King J Savory MR Wills 1981 Aluminum toxicity in relation to kidney disorders Ann Clin Lab Sci 11 337 342 1:CAS:528:DyaL3MXksF2gt7c%3D 7023347 (Pubitemid 11072072)
36. GA Block S Zeig J Sugihara GM Chertow EM Chi SA Turner, et al. 2008 Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism Nephrol Dial Transplant 23 2311 2318 1:CAS:528:DC%2BD1cXnvFShu78%3D 10.1093/ndt/gfn026 18310602 (Pubitemid 351957604)
37. WG Goodman GA Hladik SA Turner PW Blaisdell DA Goodkin W Liu, et al. 2002 The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism J Am Soc Nephrol 13 1017 1024 1:CAS:528:DC%2BD38XjtFSntL0%3D 11912261 (Pubitemid 34274098)
38. JS Lindberg SM Moe WG Goodman JW Coburn SM Sprague W Liu, et al. 2003 The calcimimetic AMG 073 reduces parathyroid hormone and calcium ι phosphorus in secondary hyperparathyroidism Kidney Int 63 248 254 1:CAS:528: DC%2BD3sXmtV2gsA%3D%3D 10.1046/j.1523-1755.2003.00720.x 12472790 (Pubitemid 35463928)